164 related articles for article (PubMed ID: 32154575)
1. Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer.
Sezer H; Yazıcı D; Deyneli O; Meriçöz Ç; Esin A; Alper E
Endokrynol Pol; 2020; 71(3):283-284. PubMed ID: 32154575
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin-Associated Diabetic Ketoacidosis.
Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
[No Abstract] [Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
4. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Rashid O; Farooq S; Kiran Z; Islam N
BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27177938
[TBL] [Abstract][Full Text] [Related]
5. Gliflozins: ketoacidosis.
Prescrire Int; 2016 Mar; 25(169):68. PubMed ID: 27152399
[TBL] [Abstract][Full Text] [Related]
6. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
Wang AY; Hou SK; Li SJ; Kao WF
Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
[No Abstract] [Full Text] [Related]
7. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
8. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Lindberg MJ; Kristensen FB; Yildiz A
Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
[TBL] [Abstract][Full Text] [Related]
9. Diabetes Drug Receives New Indication.
Aschenbrenner DS
Am J Nurs; 2017 Apr; 117(4):24-25. PubMed ID: 28333738
[No Abstract] [Full Text] [Related]
10. Empagliflozin-Associated Euglycemic Diabtetic Ketoacidosis.
Soni P; Kumar V; Saradna A; Kupfer Y
Am J Ther; 2018; 25(6):e740-e741. PubMed ID: 29746292
[No Abstract] [Full Text] [Related]
11. Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
Isaacs M; Tonks KT; Greenfield JR
Intern Med J; 2017 Jun; 47(6):701-704. PubMed ID: 28580740
[TBL] [Abstract][Full Text] [Related]
12. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
Valek R; Von der Mark J
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
[TBL] [Abstract][Full Text] [Related]
13. Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Quarella M; Walser D; Brändle M; Fournier JY; Bilz S
J Clin Endocrinol Metab; 2017 May; 102(5):1451-1453. PubMed ID: 28323955
[TBL] [Abstract][Full Text] [Related]
14. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
Zechmann S
Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
[No Abstract] [Full Text] [Related]
15. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
Kohler S; Zeller C; Iliev H; Kaspers S
Adv Ther; 2017 Jul; 34(7):1707-1726. PubMed ID: 28631216
[TBL] [Abstract][Full Text] [Related]
16. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
17. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
[TBL] [Abstract][Full Text] [Related]
18. [The SGLT2 inhibitor empagliflozin: results of EMPA-REG OUTCOMER trial].
Okamura T; Koiwai K
Nihon Yakurigaku Zasshi; 2016; 148(5):282. PubMed ID: 27803444
[No Abstract] [Full Text] [Related]
19. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
[TBL] [Abstract][Full Text] [Related]
20. Low carbohydrate diet while taking dapagliflozin: A case report and review of literature.
Paul N; Jonklaas J
Diabetes Metab Syndr; 2021; 15(1):361-363. PubMed ID: 33517150
[No Abstract] [Full Text] [Related]
[Next] [New Search]
